Related Experiment Video
Updated: Aug 15, 2026
HOX Loci Focused CRISPR/sgRNA Library Screening Identifying Critical CTCF Boundaries
Published on: March 31, 2019
CXCR4-Targeted Molecular Imaging in Hematology and Oncology
Rudolf A Werner1,2,3, Andreas K Buck4, Alexander Haug5
1Department of Nuclear Medicine, LMU University Hospital, LMU Munich, Munich, Germany; rudolf.werner@med.uni-muenchen.de.
Abstract:
C-X-C motif chemokine receptor 4 (CXCR4) has emerged as a powerful imaging target in nuclear oncology. In this regard, the PET agent [68Ga]Ga-pentixafor is promising but still evolving. In this article, we provide an overview of potentially useful imaging applications for CXCR4-targeted imaging in hemato-oncology and guidance on scan interpretation by discussing diagnostic pitfalls. We also report on theranostic efforts and how the field has been expanded toward the imaging of solid tumors. As such, this review focuses on potential clinical integration of CXCR4-targeted molecular imaging across multiple disease entities, particularly in the field of hemato-oncology.
Insights
C-X-C motif chemokine receptor 4 (CXCR4) imaging with [68Ga]Ga-pentixafor shows promise in nuclear oncology. This review explores its applications in hemato-oncology, diagnostic interpretation, and expansion to solid tumors.
Area of Science:
- Nuclear Oncology
- Molecular Imaging
- Radiochemistry
Background:
- C-X-C motif chemokine receptor 4 (CXCR4) is a key target in cancer imaging.
- [68Ga]Ga-pentixafor is an evolving positron emission tomography (PET) agent for CXCR4-targeted imaging.
- CXCR4 expression is relevant in both hematologic malignancies and solid tumors.
Purpose of the Study:
- To review the clinical applications of CXCR4-targeted molecular imaging, particularly [68Ga]Ga-pentixafor.
- To provide guidance on scan interpretation and discuss diagnostic pitfalls.
- To explore theranostic potential and the extension of CXCR4 imaging to solid tumors.
Main Methods:
- Literature review of CXCR4-targeted imaging studies.
- Analysis of [68Ga]Ga-pentixafor PET imaging in hemato-oncology.
- Discussion of diagnostic challenges and theranostic strategies.
Main Results:
- CXCR4-targeted imaging, especially with [68Ga]Ga-pentixafor, demonstrates significant potential in hemato-oncology.
- Guidance on interpreting CXCR4 PET scans and identifying potential pitfalls is provided.
- Theranostic applications and the use of CXCR4 imaging in solid tumors are expanding.
Conclusions:
- CXCR4-targeted molecular imaging, exemplified by [68Ga]Ga-pentixafor, is poised for clinical integration in various cancers.
- Accurate scan interpretation is crucial for maximizing diagnostic yield.
- The field is advancing towards theranostic applications and broader tumor coverage.
